Shanghai-Israel Fund Lead $9M Round In Rapid Medical


Rapid Medical, an Israeli company focused on the development of neurovascular interventional devices, has completed a US$9 million series B financing to advance the commercialization of the company’s minimally invasive stroke treatment and prevention products.

The round was led by Shanghai-Israel Investment Fund and Israeli investment firm BRM Group, with participation from Winnovation, a subsidiary of French Industrial group Bouygues, and U.S.-Israeli investment firm Gefen Capital.

The funding will support regulatory clearance as well as continuing to advance the European commercialization of Rapid Medical’s devices, including the Tigertriever Revascularization Device and the Comaneci Adjustable Remodeling Mesh.

Related Posts